8-K: Alzamend Neuro Secures $2.1 Million in Funding Through Ault Lending and Issues $310,000 Promissory Note

Alzamend Neuro has finalized an additional closing with Ault Lending, bringing total funding to $2.1 million, and issued a $310,000 promissory note to an accredited investor.

Summary

• Alzamend Neuro, Inc. has secured additional funding through a transaction with Ault Lending, LLC, an affiliate of the company.
• On April 29, 2024, Alzamend sold 100 shares of Series B convertible preferred stock and warrants to purchase 100,000 shares of common stock to Ault Lending for $100,000.
• This brings the total investment from Ault Lending to 2,100 shares of Series B Preferred Stock and warrants to purchase 2,100,000 common shares, for a total of $2.1 million.
• The agreement allows Ault Lending to purchase up to $6 million of Series B Preferred Stock and warrants in multiple closings.
• Additionally, Alzamend issued a promissory note with a face value of $310,000 to an accredited investor, with a purchase price of $300,000.
• The note carries a 15% annual interest rate and matures on May 13, 2024.
• Repayment of the note is secured by a guaranty from Ault Lending and Milton C. Ault, the Vice Chairman of Alzamend and CEO of Ault Alliance, Inc.

Sentiment

Score: 6

Explanation: The document indicates a positive development in securing additional funding, but the high interest rate on the promissory note and reliance on a related party temper the overall sentiment.

Positives

• Alzamend has successfully secured additional funding of $100,000 from Ault Lending.
• The total investment from Ault Lending has reached $2.1 million, indicating continued support.
• The company has access to a potential further $3.9 million in funding from Ault Lending.
• The promissory note provides an additional $300,000 in capital.

Negatives

• The promissory note has a high interest rate of 15% per annum.
• The promissory note matures quickly on May 13, 2024, requiring repayment in a short timeframe.
• The promissory note was issued with an original issuance discount of $10,000.

Risks

• The company is reliant on Ault Lending for a significant portion of its funding.
• The short-term nature of the promissory note could create a liquidity challenge if not repaid or refinanced.
• Failure to repay the promissory note could trigger an event of default and a higher interest rate of 22.99%.

Future Outlook

The agreement with Ault Lending allows for potential additional funding up to $6 million, which could provide further capital for the company's operations and development.

Industry Context

This funding activity is typical for a development-stage biotech company like Alzamend, which often relies on private placements and debt financing to fund research and development.

Comparison to Industry Standards

• Many biotech companies at a similar stage of development rely on similar funding mechanisms, such as convertible preferred stock and short-term debt.
• The 15% interest rate on the promissory note is relatively high, which may reflect the risk associated with the company's stage of development and the short maturity of the note.
• The use of a related party, Ault Lending, for a significant portion of the funding is not uncommon but requires careful scrutiny to ensure fair terms.
• Comparable companies often use a mix of equity and debt financing, with the specific terms varying based on the company's financial health and market conditions.

Related Party Transactions

• The transaction with Ault Lending, an affiliate of the company, is a related party transaction.

Stakeholder Impact

• Shareholders may view the additional funding as a positive sign for the company's future.
• The high interest rate on the promissory note could be a concern for shareholders.
• Employees may benefit from the increased financial stability provided by the funding.
• Creditors may be impacted by the new debt obligations.

Next Steps

• Alzamend will need to repay the $310,000 promissory note by May 13, 2024.
• The company may seek further funding from Ault Lending under the existing agreement.
• Alzamend will likely continue to explore other financing options to support its operations.

Key Dates

Keywords

Alzamend Neuro, Ault Lending, Series B Preferred Stock, Warrants, Promissory Note, Funding, Convertible Preferred Stock, Capital Raise, Debt Financing